参考文献/References:
[1] Schlumberger M,Leboulleux S,Catargi B,et al.Outcome after ablation in patients with low-risk thyroid cancer(ESTIMABL1):5-year follow-up results of a randomised,phase 3,equivalence trial[J].Lancet Diabetes Endocrinol,2018,6(8):618-26.DOI:10.1016/S2213-8587(18)30113-X.
[2] Tran B,Roshan D,Abraham E,et al.An analysis of the american joint committee on cancer 8th edition T staging system for papillary thyroid carcinoma[J].J Clin Endocrinol Metab,2018,103(6):2199-2206.DOI:10.1210/jc.2017-02551.
[3] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.DOI:10.3760/cma.j.issn.0253-3766.2019.01.008.
[4] 中华医学会超声医学分会浅表器官和血管学组,中国甲状腺与乳腺超声人工智能联盟.2020甲状腺结节超声恶性危险分层中国指南:C-TIRADS[J].中华超声影像学杂志,2021,30(3):185-200.DOI:10.3760/cma.j.cn131148-20210205-00092.
[5] Chen DW,Reyes-Gastelum D,Wallner LP,et al.Disparities in risk perception of thyroid cancer recurrence and death[J].Cancer,2020,126(7):1512-21.DOI:10.1002/cncr.32670.
[6] Asban A,Chung SK,Xie R,et al.Gender and racial disparities in survival after surgery among papillary and patients with follicular thyroid cancer:a 45-year experience[J].Clin Med Insights Endocrinol Diabetes,2019,12:1179551419866196.DOI:10.1177/1179551419866196.
[7] Amin MB, Greene FL, Edge SB, et al.The Eighth Edition AJCC Cancer Staging Manual:Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J].CA Cancer J Clin,2017,67(2):93-99.DOI:10.3322/caac.21388.
[8] Giani C,Torregrossa L,Piaggi P,et al.Outcome of classical(CVPTC)and follicular(FVPTC)variants of papillary thyroid cancer:15 years of follow-up[J].Endocrine,2020,68(3):607-616.DOI:10.1007/s12020-020-02229-0.
[9] Brito JP,Hay ID.Management of papillary thyroid microcarcinoma[J].Endocrinol Metab Clin North Am,2019,48(1):199-213.DOI:10.1016/j.ecl.2018.10.006.
[10] Ji YB,Song CM,Kim D,et al.Efficacy of hemithyroidectomy in papillary thyroid carcinoma with minimal extrathyroidal extension[J].Eur Arch Otorhinolaryngol,2019,276(12):3435-3442.DOI:10.1007/s00405-019-05598-z.
[11] Kwon H,Jeon MJ,Kim WG,et al.A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factor matched cohort study[J].Eur J Endocrinol,2017,176(4):371-378.DOI:10.1530/EJE16-0845.
[12] Patel KN,Yip L,Lubitz CC,et al.The American Association of Endocrine Surgeons guidelines for the definitive surgical management of thyroid disease in adults[J].Ann Surg,2020,271(3):e21-e93.DOI:10.1097/SLA.0000000000003580.
[13] Haugen BR,Alexander EK,Bible KC,et al.2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J].Thyroid,2016,26(1):1-133.DOI:10.1089/thy.2015.0020.
[14] Perrier ND,Brierley JD,Tuttle RM.Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J].CA Cancer J Clin,2018,68(1):55-63.DOI:10.3322/caac.21439.
[15] Zhi J,Wu Y,Hu L,et al.Assessment of the prognostic value and N1b changes of the eighth TNM/AJCC staging system for differentiated thyroid carcinoma[J].Int J Clin Oncol,2020,25(1):59-66.DOI:10.1007/s10147-019-01522-x.
[16] Shteinshnaider M,Muallem Kalmovich L,Koren S,et al.Reassessment of differentiated thyroid cancer patients using the Eighth TNM/AJCC classifification system:a comparative study[J].Thyroid,2018,28(2):201-209.DOI:10.1089/thy.2017.0265.
[17] van Velsen EFS,Stegenga MT,Van Kemenade FJ,et al.Comparing the prognostic value of the Eighth edition of the American Ioint Committee on Cancer/Tumor node metastasis staging system between papillary and follicular thyroid cancer[J].Thyroid,2018,28(8):976-981.DOI:10.1089/thy.2018.0066.
[18] Turk AT,Asa SL,Baloch ZW,et al.Interobserver variability in the histopathologic assessment of extrathyroidal extension of well differentiated thyroid carcinoma supports the new American Joint Committee on cancer Eighth edition criteria for tumor staging [J].Thyroid,2019,29(5):619-624.DOI:10.1089/thy.2018.0286.
[19] Ho AS,Luu M,Barrios L,et al.Incidence and Mortality Risk Spectrum Across Aggressive Variants of Papillary Thyroid Carcinoma[J].JAMA Oncol,2020,6(5):706-713.DOI:10.1001/jamaoncol.2019.6851.
[20] American Thyroid Association(ATA)Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J].Thyroid,2009,19(11):1167-1214.DOI:10.1089/thy.2009.0110.
[21] 中国医师协会外科医师分会甲状腺外科医师委员会,中国研究型医院学会甲状腺疾病专业委员会.分化型甲状腺癌术后管理中国专家共识(2020版)[J].中国实用外科杂志,2020,40(9):1021-1028.DOI:10.19538/j.cjps.issn1005-2208.2020.09.04.
相似文献/References:
[1]孟召伟 ?宋兴华 谭建 张桂芝 何雅静 贾强 张富海 王任飞 郑薇 李雪 张建萍.不同放射性活度I131清除分化型甲状腺癌患者残留甲状腺的荟萃分析[J].国际内分泌代谢杂志,2015,(01):16.[doi:10.3760/cma.j.issn.1673-4157.2015.01.004]
Meng Zhaowei,Song Xinghua,Tan Jian,et al.Different activities of 131I for remnant thyroid ablation in patients with differentiated thyroid cancer: a meta analysis[J].International Journal of Endocrinology and Metabolism,2015,(01):16.[doi:10.3760/cma.j.issn.1673-4157.2015.01.004]
[2]陆东宁,徐加杰,葛明华.甲状腺球蛋白在分化型甲状腺癌复发转移诊治中的研究进展[J].国际内分泌代谢杂志,2022,42(06):465.[doi:10.3760/cma.j.cn121383-20210930-09092]
Lu Dongning,Xu Jiajie,Ge Minghua..Research progress of thyroglobulin in the diagnosis and treatment of recurrence and metastasis of differentiated thyroid cancer[J].International Journal of Endocrinology and Metabolism,2022,42(01):465.[doi:10.3760/cma.j.cn121383-20210930-09092]